

## Contents

**Preface** XIX

**List of Contributors** XXIII

<b>1</b>	<b>Introduction to Sample Management</b>	<b>1</b>
	<i>William P. Janzen and Andy Zaayenga</i>	
	References	6
<b>2</b>	<b>Generating a High-Quality Compound Collection</b>	<b>9</b>
	<i>Philip B. Cox and Anil Vasudevan</i>	
2.1	Defining Current Screening Collections	9
2.2	Design Criteria for Enriching a Compound Collection with Drug-Like Compounds	10
2.2.1	Physicochemical Tailoring of a Compound Collection	10
2.2.2	Lipophilicity Design Considerations	11
2.2.3	Other Physicochemical Roadblocks	14
2.2.4	Assessing Risk – from Rule of 5 to Rule of 3/75	18
2.2.5	Tools Enabling Desk Top <i>In Silico</i> Design	19
2.3	Concluding Remarks	20
	References	20
<b>3</b>	<b>Assessing Compound Quality</b>	<b>23</b>
	<i>Ioana Popa-Burke, Stephen Besley, and Zoe Blaxill</i>	
3.1	Introduction	23
3.2	Process Quality and Analytical Quality in Compound Management	24
3.2.1	Process Quality (QA)	25
3.2.2	Analytical Quality (Sample QC)	27
3.3	Identity	28
3.4	Purity/Stability	32
3.4.1	Measuring Purity	32
3.4.2	Determining the Most Appropriate Purity Cut-Off for Solutions	37
3.4.3	Stability of Solutions	38

3.5	Concentration/Solubility	39
3.6	Conclusions	41
	Acknowledgments	41
	References	42
	Further Reading	44
<b>4</b>	<b>Delivering and Maintaining Quality within Compound Management</b>	<b>45</b>
	<i>Isabel Charles</i>	
4.1	Introduction	45
4.2	What is Quality from a Compound Management Perspective?	46
4.3	Storage and Delivery of Samples in Solution	47
4.4	Intercepting Low Purity	49
4.5	Storage and Delivery of Solids	51
4.6	Automation Quality Control and Reliability	52
4.7	High-Quality Data Management	54
4.8	Conclusion	55
	Acknowledgments	56
	References	56
<b>5</b>	<b>Obtaining and Maintaining High-Quality Tissue Samples: Scientific and Technical Considerations to Promote Evidence-Based Biobanking Practice (EBBP)</b>	<b>59</b>
	<i>Lisa B. Miranda</i>	
5.1	Introduction	59
5.1.1	Current Issues and Impediments to Benchmark Level Biospecimen Research	59
5.1.2	The Role of the Research Protocol in Preserving Biospecimen Quality	60
5.1.3	Rationale for Best Practice Integration into Sample Management Procedures and Protocols	61
5.2	The Path toward Integration of Evidence-based Biobanking Practice	62
5.2.1	Conceptual Foundations of Evidence-based Biobanking Practice	62
5.2.2	The Pre- and Post-Acquisition Analytic Variable Relationship to EBBP	63
5.2.3	The Biospecimen Lifecycle Concept: a Framework to Aid EBBP Protocol Design	64
5.3	Integrating Evidence-based Biobanking Practice into Sample Protocols	66
5.3.1	Protocol Planning for EBBP-based Sample Management	66
5.3.2	Crucial Scientific and Technical Considerations for EBBP Protocol Design	68
5.3.3	Utilizing Publication Reporting Guidelines to Guide EBBP Protocol Design	73

5.4	Final Thoughts and Recommendations	74
5.4.1	Proposed Staging System to Qualify EBBP Related Data	74
5.4.2	Revisiting Crucial Considerations Related to Implementation of EBBP	77
5.4.3	Strategies to Optimize Real-Time Implementation of EBBP	78
	References	79
<b>6</b>	<b>Thinking Lean in Compound Management Laboratories</b>	<b>83</b>
	<i>Michael Allen</i>	
6.1	The Emergence of 'Lean Thinking'	83
6.2	The Application of 'Lean Thinking'	83
6.3	Lean Thinking in Drug Discovery	86
6.4	A Lean Laboratory Toolbox	87
6.4.1	Defining Value	87
6.4.2	Understanding the Current Process – Process Mapping	88
6.4.3	Identifying Waste	88
6.4.4	Standardized Work, Future State Mapping, and Continuous Improvement	89
6.4.5	Batch Size Reduction, Changeover Time Reduction, and Workload Smoothing	90
6.4.6	5S and Kanban	92
6.4.7	Lean Layouts and Flow	95
6.4.8	Total Productive Maintenance	96
6.4.9	Theory of Constraints (TOC)	99
6.4.10	The Visual Workplace	100
6.4.11	Engaging Staff	100
6.5	Streamlining Compound Processing –An Example	101
6.6	Summary	103
	References	105
<b>7</b>	<b>Application of Supply Management Principles in Sample Management</b>	<b>107</b>
	<i>Paul A. Gosnell</i>	
7.1	Introduction	107
7.2	Common Pitfalls of Sample Management	107
7.2.1	One Size Does Not Fit All	108
7.3	Sample Management and Supply Chain Concepts	108
7.3.1	Goods and Services – Classification and Strategy	109
7.4	Implementing the Sample Management Strategy	111
7.5	Sample Management Organization	111
7.6	Sample Management Informatics	113
7.7	Avoid Monolithic Silos of Excellence	114
7.8	Position and Synchronize Inventory	115
7.9	Expand the Sample Management Boundary	117
7.10	Measuring and Assessing Effectiveness and Quality	118

7.11	Conclusions	119
	References	120

## **8 Solid Sample Weighing and Distribution 121**

*Michael Gray and Snehal Bhatt*

8.1	The Practicalities and Technology of Weighing Solid Compounds	121
8.1.1	Introduction	121
8.1.2	Manual Weighing	122
8.1.3	Automated Weighing	123
8.1.4	Volatile Solvent Transfer	125
8.1.5	Sample Weighing –Summary and Conclusions	126
8.2	Logistical Challenges of Transportation of Small Molecules	127
8.2.1	Introduction to Transportation	127
8.2.2	Complexity of Logistics and Compliance Challenges of Supply Chain	129
8.2.3	Regulations and Procedures for Shipping Hazardous Materials, Hazardous Material in Small, Limited Quantity, with Dry Ice	131
8.2.3.1	Domestic Regulations	131
8.2.3.2	General Shipping Procedures and Associated Regulations	132
8.2.3.3	International Regulations	134
8.2.4	Cold Supply Chain Challenges	136
8.2.5	Collaboration with Subject Experts	137
8.2.5.1	Process Development and Standardization	138
8.2.6	Software Solutions	140
8.2.7	Conclusion	141
	References	142

## **9 Managing a Global Biological Resource of Cells and Cellular Derivatives 143**

*Frank P. Simone and Raymond H. Cypess*

9.1	Introduction	143
9.2	Diversity of Collections	144
9.3	Sourcing and Acquisition	148
9.4	Authentication and Characterization	149
9.4.1	Viability	151
9.4.2	Cellular Morphology	151
9.4.3	Microbial Contamination	151
9.4.4	Mycoplasma Detection	151
9.4.5	Virus Testing	151
9.4.6	Short Tandem Repeat (STR) Profiling	152
9.4.7	Isoenzyme Analysis	152
9.4.8	Cox 1 and CO1	152
9.4.9	Karyotyping	152
9.4.10	Immunophenotyping and Immunochemistry	153

9.4.11	Pico Green and PI	153
9.5	Cryopreservation, Storage, and Production	153
9.6	Data Management	154
9.7	Quality and Standards	155
9.8	Order Fulfillment and Distribution	157
9.9	Offsite Biorepository Management	158
9.10	Regulatory and Legal Compliance	159
9.11	Ownership and Intellectual Property Management	160
9.12	Collaborations	161
9.13	Conclusion	162
	References	163
<b>10</b>	<b>Development of Automation in Sample Management</b>	<b>165</b>
	<i>Gregory J. Wendel</i>	
10.1	Introduction	165
10.2	Historical Background	165
10.3	Automation of Sample Management Today	167
10.4	System Building Blocks	169
10.4.1	Storage Systems	169
10.4.2	Liquid Handling	169
10.4.3	Accessories	170
10.4.4	Plate Handling, Integration	170
10.4.5	Data Management	171
10.5	Storage Systems	171
10.5.1	Features	171
10.5.1.1	Size	171
10.5.1.2	Format	172
10.5.1.3	Temperature	172
10.5.1.4	Environment	172
10.5.1.5	Internal Manipulation	172
10.5.1.6	Robotic Interface	172
10.5.2	Example Hardware	173
10.6	Liquid Handler	175
10.6.1	Features	175
10.6.1.1	Deck Size	176
10.6.1.2	Head Format	176
10.6.1.3	Head Volume Range	176
10.6.1.4	Individual Channels	176
10.6.1.5	Gripper	177
10.6.1.6	Tip Loading	177
10.6.1.7	Barcode Reader	177
10.6.1.8	Tube/Vial Gripping	177
10.6.1.9	Integration Options	177
10.6.1.10	On-Deck Accessories	177
10.6.2	Example Hardware	178

10.7	Accessories	180
10.7.1	Common Devices	180
10.7.1.1	Plate Seal/Unseal	180
10.7.1.2	Plate Label	181
10.7.1.3	Tube Sorting	181
10.7.1.4	Centrifuge	182
10.7.1.5	Mixing	182
10.7.1.6	Bulk Reagent Addition	183
10.7.1.7	Tube Inspection	184
10.8	Plate Handling, Integration	184
10.9	Case Study: Evolution of a Compound Management Group	186
10.9.1	Background	186
10.9.2	Starting Condition	187
10.9.3	Roadmap to Evolution	188
10.9.4	Current Holdings Integrity	188
10.9.5	Automated Solutions	189
10.9.5.1	Storage Format	190
10.9.5.2	Storage Systems	190
10.9.5.3	Liquid Handling	190
10.9.5.4	Accessories	191
10.9.5.5	System Integration	191
10.9.5.6	Integrated vs Walk-Up	192
10.9.6	Workflow Standardization	193
10.9.6.1	Screening Plates	193
10.9.6.2	Cherry-Picks	194
10.9.6.3	Compound Registration	195
10.10	Results	196
	References	197
<b>11</b>	<b>Applications of Acoustic Technology</b>	<b>199</b>
	<i>Eric Tang, Colin Bath, and Sue Holland-Crimmin</i>	
11.1	Introduction	199
11.2	Compound-Handling Challenges in Drug Discovery	201
11.3	Acoustic Drop Ejection –Performance, Quality Assurance, and Platform Validation	203
11.3.1	Precision	203
11.3.2	Quality Assurance – Non-Invasive DMSO Hydration Monitor	203
11.3.3	Platform Validation	205
11.4	Acoustic-Assisted Compound Solubilization and Mixing	206
11.4.1	Sonication	207
11.4.2	Ultrasonic Mixing	207
11.5	Acoustic Applications in Drug Discovery	209
11.5.1	HTS and Assay-Ready Plates – Compound Reformatting and Generic Dose Response Studies	209
11.5.2	Compound Dosing in Cell-Based Screening Applications	211

11.5.3	Cell-Based Combination Screening	215
11.6	Emerging Applications	216
11.6.1	Acoustic Transfer of Aqueous Reagents and Biologics	216
11.6.2	Cell Suspension Transfer	217
11.6.3	Matrix Deposition for MALDI Imaging Mass Spectrometry	217
	References	218
<b>12</b>	<b>Enhancing Biorepository Sample Integrity with Automated Storage and Retrieval</b>	<b>221</b>
	<i>Johann van Niekerk</i>	
12.1	The Emerging Growth of Biobanking	221
12.1.1	The New Face of an Old Practice	221
12.1.2	Source Material for Post-Genomic Age Research	221
12.1.3	Different Operational Models in Biobanking	222
12.1.3.1	Population Biobanks	222
12.1.3.2	Disease-Oriented Biobanks for Epidemiology	223
12.1.3.3	Disease-Oriented General Biobanks	223
12.1.4	Why Are Modern Biobanks Needed?	223
12.1.5	The Quest for Biospecimen Quality in Biorepositories	223
12.2	Automated Storage and Retrieval in a Biorepository	225
12.2.1	Inventory Management	225
12.2.2	Automation – Self-Controlling Processes	225
12.2.3	Maintaining Biospecimen Value	226
12.2.3.1	Biospecimen Integrity	226
12.2.3.2	Data Integrity	228
12.2.4	Advantages of Automated Biospecimen Management	232
12.2.4.1	Stable Storage Conditions	232
12.2.4.2	Operational Reliability	232
12.2.4.3	Efficiency and Convenience of Operation	234
12.2.4.4	Restricted Physical Access to Stored Content	235
12.2.4.5	Redeployment or Reduction of Full-Time Employees	236
12.2.4.6	Configuration Flexibility – Fit for Purpose	236
12.3	Configuration of an Automated Biorepository	236
12.3.1	Modularity	236
12.3.1.1	Storage Chamber	237
12.3.1.2	Robotic Object Handling	237
12.3.1.3	Functional Modules – Execution of Specific Tasks	238
12.3.2	Scalability	239
12.3.2.1	Expansion of Storage Capacity	240
12.3.2.2	Increased Storage System Performance	240
12.4	Conclusions	241
	References	241

### 13 Information Technology Systems for Sample Management 243

*Brian Brooks*

- 13.1 Sample Registration 243
  - 13.1.1 Why the Need for Registration? 243
  - 13.1.2 Assigning and Using Identifiers at Different Levels 245
  - 13.1.3 Preparation Numbering 246
  - 13.1.4 Sample Numbering 246
  - 13.1.5 Methods for Naming Compounds 246
  - 13.1.6 Some History to Compound Registration 247
  - 13.1.7 Business Rules for Compound Registration 247
    - 13.1.7.1 Number Format 248
    - 13.1.7.2 Compound Number Prefix 248
    - 13.1.7.3 Purity 248
    - 13.1.7.4 Salts 249
    - 13.1.7.5 Stereochemistry 249
    - 13.1.7.6 Enantiomers and Racemic Mixtures 250
    - 13.1.7.7 Standardization of Charge Form 250
    - 13.1.7.8 Tautomerism 250
    - 13.1.7.9 Radioactivity 250
    - 13.1.7.10 Project Codes, Site Codes, Country Codes 251
    - 13.1.7.11 Larger Molecules – of Known Structure 251
    - 13.1.7.12 Larger Molecules – of Unknown Structure 252
    - 13.1.7.13 Combinatorial Mixtures 252
    - 13.1.7.14 Inorganic Compounds 252
    - 13.1.7.15 Development Compounds, Outside Publications, Generic, and Trade Names 252
  - 13.1.8 The Role of the Chemical Registrar 253
- 13.2 Intellectual Property and Laboratory Notebooks 253
- 13.3 Some Observations on Information Technology 254
- 13.4 Biological Data Management 255
  - 13.4.1 The Corporate Biological Screening Database (CBSD) 255
  - 13.4.2 Data Entry Tools 257
  - 13.4.3 Database Querying 258
  - 13.4.4 Special Data Types 261
  - 13.4.5 Database Designs 261
- Dedication and Acknowledgments 263

### 14 Key Features of a Compound Management System 265

*Clive Battle*

- 14.1 Why Do We Need Compound Management Information Technology Systems? 265
- 14.2 Compound Management Software 266
  - 14.2.1 Inventory Management 266
    - 14.2.1.1 Data Storage 267
    - 14.2.1.2 Inventory Tracking 267



14.2.1.3	Inventory Browsing	267
14.2.1.4	Importing Inventory Items	267
14.2.1.5	Editing Inventory Items	267
14.2.1.6	Organizing the Inventory	267
14.2.2	Ordering	268
14.2.2.1	Web-Based Ordering	268
14.2.2.2	Sample Naming	268
14.2.2.3	Definition of an Order	268
14.2.2.4	Order Validation	268
14.2.2.5	Order Approval	269
14.2.2.6	Restrictions	269
14.2.2.7	Queries	269
14.2.2.8	Order Status Notifications	269
14.2.3	Workflow Management	269
14.2.3.1	Workflow Steps	269
14.2.4	Fulfillment	270
14.2.4.1	Offline Instrument Integration	270
14.2.4.2	Online Instrument Integration	270
14.2.4.3	Offline vs Online	271
14.2.4.4	Despatch	271
14.2.4.5	Reports and Metrics	271
14.2.5	Interfaces with External Systems	271
14.2.5.1	Chemical Registration System	271
14.2.5.2	External Ordering System	272
14.2.5.3	Results Analysis	272
14.3	Benefits of Commercially Available Compound Management Systems	272
	References	273
<b>15</b>	<b>What Does an HTS File of the Future Look Like?</b>	<b>275</b>
	<i>François Bertelli</i>	
15.1	Introduction	275
15.2	History of Compounds Collection for HTS	276
15.3	Impact of High-Throughput Chemistry on Corporate Files	277
15.4	Chemical Library Management	278
15.5	The Concept of Drug-Likeness and the Lipinski Rules	279
15.5.1	Drug-Like	280
15.5.2	Lead-Like	282
15.6	Quality versus Quantity	283
15.7	The Emergence of the Subsets: Fragment, G-Protein-Coupled Receptor (GPCR), Ion Channel, Kinase, Protein–Protein Interaction, Chemogenomics, Library Of Pharmacologically Active Compounds (LOPAC), Central Nervous System (CNS), and Diversity	285
15.7.1	‘Cherry Picking’ from Virtual Space	286
15.7.2	Diverse Subsets	287

15.7.3	Creation of the Global Diversity Representative Subset (GDRS)	288
15.7.4	Plate-Based Diversity Set (PBDS)	290
15.8	Re-designing the Corporate File for the Future	291
15.8.1	Pooling Compounds Moving Forward	291
15.8.2	Re-designing the Future File	296
15.9	Future Routes for Hit Identification	299
	References	301
<b>16</b>	<b>New Enabling Technology</b>	<b>305</b>
	<i>Neil Hardy, Ji Yi Khoo, Shoufeng Yang, Holger Eickhoff, Joe Olechno, and Richard Ellson</i>	
16.1	Introduction	305
16.2	A Drop-On-Demand Printer for Dry Powder Dispensing	307
16.2.1	Dispensing Device Setup	308
16.2.2	Effect of Powder Dispensing Parameters on Micro-feeding	309
16.3	Piezo Dispense Pens: Integrated Storage and Dispensing Devices and their Potential in Secondary Screening and Diagnostic Manufacturing	312
16.3.1	An Introduction to Piezo Dispensers	312
16.3.2	PDP Mode of Operation and Its Advantages	313
16.3.3	PDPs in the High-Throughput Screening Environment	317
16.3.4	The Instrument to Operate PDPs in a Pharmaceutical Laboratory: sciSWIFTER	319
16.3.5	PDPs for the Sterile and Contamination-Free Production of <i>In Vitro</i> Diagnostics	321
16.3.6	Summary and Outlook	322
16.4	Future Directions in Acoustic Droplet Ejection Technology	323
16.4.1	Introduction	323
16.4.2	Stretching the Boundaries of Current ADE Uses	323
16.4.2.1	High-Viscosity Fluids	324
16.4.2.2	Low-Surface-Tension Fluids	326
16.4.2.3	Layered, Bi-Phasic Fluids	329
16.4.2.4	Combinatorial Chemistry	331
16.4.2.5	Particle Formation	332
16.4.2.6	Precision Coating	332
16.4.2.7	Touchless Transfer of Dangerous Materials	333
16.4.2.8	Assay Miniaturization	334
16.4.2.9	Transfection via Sonoporation	336
16.4.2.10	Expanded Reporting Capabilities	336
16.4.2.11	Transfer of Droplets of Different Volume – Smaller Droplets	337
16.4.2.12	Transfer of Droplets of Different Volume – Larger Droplets	338
16.4.3	Expanded Auditing Capabilities	338
16.4.3.1	Auditing for Volume	339
16.4.3.2	Auditing for Restoration	340
16.4.3.3	Auditing for Solute Information	341

16.4.3.4	Auditing Bi-Phasic Solutions	342
16.4.3.5	Auditing for Sample Quality	342
16.4.3.6	Frequency-Domain Analysis	343
16.4.4	New Software Advances	344
16.4.4.1	Improved Meniscus Scan	344
16.4.5	ADE Summary	344
16.5	Closing Remarks	347
	References	347
<b>17</b>	<b>The Impact of Future Technologies within Biobanking</b>	<b>351</b>
	<i>Manuel M. Morente, Laura Cereceda, and María J. Artiga</i>	
17.1	Introduction	351
17.2	The Role of Biobanks in Biomedical Research	351
17.2.1	Biobanking Activity Is Based on Commitments	351
17.2.2	Scientific Commitment: Biobanks Must Be Open to Updating and Redefinition According to the Ever-Changing Scientific Requirements	352
17.2.3	Personalized Medicine on the Horizon: Biobanks for Better Health	353
17.3	The Increasing Complexity of Biobanking	354
17.3.1	Biobanks versus Sample Collections	354
17.3.2	Biobank Diversity	355
17.3.3	Biobanking, a Young Discipline	356
17.4	Future Technologies and Biobanking: How Could New Technologies Affect the Daily Activities of Biobanks?	356
17.4.1	IT Solutions and Challenges	357
17.4.2	Storage Mechanization	359
17.4.3	Virtual Microscopy	360
17.4.4	Nanotechnology and Quality Control	360
17.4.5	Tissue Microarrays	361
17.4.6	New Fixatives	362
17.4.7	Robotized RNA/DNA/Protein Extraction	363
17.5	The Future of Biobanking Does Not Depend on Technological Developments Alone	363
17.6	Conclusions	364
	Acknowledgments	364
	References	364
<b>18</b>	<b>Outsourcing Sample Management</b>	<b>367</b>
	<i>Sylviane Boucharens and Amelia Wall Warner</i>	
18.1	Outsourcing in the Pharmaceutical Industry	367
18.1.1	Economic and Organizational Advantage of Outsourcing	368
18.1.2	Sourcing the Right Partner	368
18.1.3	Compound Inventory – Cost of Ownership	369
18.1.4	Areas of Outsourcing in Compound Management	371

18.1.5	Outsourcing to Exploit a Key Asset	371
18.1.6	Future Developments	373
18.2	Outsourcing Biological Specimen Collections	374
18.2.1	Outsourcing the Biorepository: Determining the Model	375
18.2.2	Key Competencies for Outsourced Biorepository Vendors	376
18.2.3	Internal Oversight for Outsourced Biorepository Vendors	377
18.2.4	Lessons Learned	377
18.3	Conclusions	378
	Acknowledgments	378
	References	378
<b>19</b>	<b>Sample Management Yesterday and Tomorrow</b>	<b>381</b>
	<i>Terry Wood and Mark Wigglesworth</i>	
19.1	The Role of Sample Management	381
19.2	Automation of Compound Management	382
19.3	Compound Integrity	384
19.4	Reduction of Redundancy	386
19.5	The Future of Sample Management?	387
19.5.1	Introduction	387
19.5.2	The Cost of Drug Discovery	388
19.5.3	Independent Service Providers	388
19.5.4	Alternative Models of Drug Discovery	389
19.6	Concluding Remarks	390
	References	391
	<b>Index</b>	<b>393</b>